Seattle Genetics Inc. Message Board
-
What other biotechs are you guys looking at these days?
Just curious. I've been looking at MAPP recently. Missed the boat on VRML after having it on my watchlist for a while :(
-
How did Riceen know that SGEN will finish at $25.56? Today he predicts $26.21.
-
How did Riceen know it would finish at $27.62 this week? Who is he? Is he a stock guru?
Sentiment: Buy
- 2 Replies to credtrtrteingyt
-
Analyst Mr. Riceen also put an $28 price target on SGEN. He predicted that the company will increase its earnings per share at an annual rate of 7 to 14 percent, slightly below the 15 percent he previously forecasted.
He also wrote last week it would finish at $23.12. He was off a penny. In today's letter he said SGEN will close Monday at $23.45. Being 87% right there are no guarantee's, but this guy is a Guru. -
NKTR got some very good news for their OIC candidate NKTR-118 yesterday. The drug Relistor was supposed to be formidible near term competition. Yesterday, SLXP admitted that they completely botched the Phase III long term safety study for Relistor, and they show no interest in performing one. The FDA won't approve Relistor for chronic indications without it. This leaves Relistor dead as a doornail.
-
Been running with ALNY, ISIS and SPHRY
Super Speculatives: AEMD CTSO SBOTF -
I have SGEN and ARNA, had IMGN but cashed out.
-
I only buy what Riceen recommends.
- 1 Reply to greatdaysarrrcoming
-
Riceen is a great seer of sorts he is the Evangeline Adams of the 1920's
-
Just thought I'd bump this, hope that's ok. SGEN seems to have one of the few bioteach boards not populated by lunatics with a lot of good analysis. Has anyone added new stuff to their portfolio? I just got in CLSN the other day after it dropped 8-9% or so.
-
Thoughts on AMRN price action immediately following FDA decision if approved with NCE?
-
ZIOP -- ZIOPHARM Oncology. It recently pulled back to $5.70 for a decent entry point.
-
ECYT
google>> ecyt bioworld
crazy thing is even after merck deal and 120mil upfront pmt..ECYT mkt cap only 280 mil -
I love ZIOP. I think its still somewhat overlooked by the majority of biotech investors. They have a great CEO and did a partnership with Randall Kirk's(Forbes calls him the most successful biotech investor of all time) privately held Intrexon. He is now a major shareholder of ZIOP and has brought Fidelity and the Baker Bros into the company as large shareholders. In fact during the last secondary(this Jan)the raise was done at a higher price than the stock had traded in months(signals strong interest). There is currently lots of speculation of a partnership involving the lead compound which has completed one phase 3 trial(results expected by year end)for soft tissue sarcoma and just starting a pivotal phase 3 for small cell lung cancer. Also major news is expected for the lead Interexon/ZIOP compound in the 2H '12. Lots of catalyst for the next 6 months. Not much risk near term.
- 1 Reply to limegoldconvertible68
-
More about NKTR (AFFY too).
AFFY on a big run because of Omontys deal with Fresenius. Omontys is to Epogen what Neulasta was to Neupogen. Both Omontys and Neulasta are based on NKTR peg technology.
NKTR-228 is a pegged calcimimetic that I'm hoping will get an IND later this year. The main calcimimetic on the market, Sensipar, has all kinds of problems. It is oral (a plus), but needs to be taken daily and causes all kinds of digestive problems. NKTR-228 could be administered during dialysis. Something to keep an eye on.
- View More Messages
-